What is DHR stock price target for 2026?

WallStSmart's 12-month price target for Danaher Corporation is $151.39, representing 15.4% downside from the current price of $178.95.

What is DHR stock forecast?

Danaher Corporation forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is DHR undervalued based on price targets?

Our DCF intrinsic value for Danaher Corporation is $136.44, against a current price of $178.95. The margin of safety is -31.01%.

DHR

Danaher Corporation

NYSE: DHR · HEALTHCARE · DIAGNOSTICS & RESEARCH

$178.95

+0.08% today

Updated 2026-04-29

Market cap

$125.45B

P/E ratio

34.35

P/S ratio

5.06x

EPS (TTM)

$5.16

Dividend yield

0.76%

52W range

$175 – $242

Volume

4.3M

Market cap

$125.45B

P/E ratio

34.35

P/S ratio

5.06x

EPS (TTM)

$5.16

Dividend yield

0.76%

52W range

$175 – $242

Volume

4.3M

Danaher Corporation (DHR) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$178.95

Consensus

$250.00

+39.70%

2030 Target

$592.47

+231.08%

DCF

$136.44

-31.01% MoS

Current price

$178.95

Analyst consensus

$250.00

+39.70%

2030 Target

$592.47

+231.08%

Intrinsic (DCF)

$136.44

-31.01% MoS

15 analysts:

7 Buy2 Hold0 Sell

Management guidance

No specific CEO revenue targets disclosed for 2026-2030 in available data. Company confirmed Q4 2025 results and increased dividend 25%, but forward guidance limited to near-term analyst consensus. Masimo $9.9B acquisition expected to close mid-2026, adding ~$1.2B annual revenue.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$993.82

$35.2B Rev × 20x P/S

Base case (2030)

$592.47

$35.2B Rev × 12x P/S

Bear case (2030)

$401.35

$35.2B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$23.9B	$23.9B	$24.6B	$26.9B	$28.6B	$30.6B	$32.8B	$35.2B
Revenue growth	—	-0.1%	2.9%	9.4%	6.5%	6.6%	7.4%	7.3%
EPS	$8.52	$7.49	$7.80	$8.49	$9.21	$10.05	$10.95	$11.85
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$458.69	$477.80	$516.02	$554.25	$592.47

Catalysts & risks

Growth catalysts

+ Masimo acquisition close (expected mid-2026) adding diagnostic device capabilities and ~$1.2B revenue

+ Bioprocessing segment recovery as early-stage biotech funding normalizes post-2026

+ Expansion in life sciences tools and precision diagnostics (core high-margin segments)

Key risks

- China policy headwinds and geopolitical tensions impacting biotech/pharma customer spending

- Bioprocessing demand weakness persisting longer than expected due to depressed biotech funding environment

- Integration execution risk on $9.9B Masimo acquisition; potential margin dilution in near-term

Methodology

Danaher Corporation's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 15 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.